BR112021026389A2 - Métodos e materiais para expansão direcionada de células t reguladoras - Google Patents

Métodos e materiais para expansão direcionada de células t reguladoras

Info

Publication number
BR112021026389A2
BR112021026389A2 BR112021026389A BR112021026389A BR112021026389A2 BR 112021026389 A2 BR112021026389 A2 BR 112021026389A2 BR 112021026389 A BR112021026389 A BR 112021026389A BR 112021026389 A BR112021026389 A BR 112021026389A BR 112021026389 A2 BR112021026389 A2 BR 112021026389A2
Authority
BR
Brazil
Prior art keywords
mammal
materials
methods
regulatory
cells
Prior art date
Application number
BR112021026389A
Other languages
English (en)
Inventor
Derek Vandyke
Jamie Spangler
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of BR112021026389A2 publication Critical patent/BR112021026389A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

métodos e materiais para expansão direcionada de células t reguladoras. este documento se refere a métodos e materiais para expansão direcionada de células t reguladoras (tregs). por exemplo, uma ou mais proteínas de fusão de anticorpo/citocina de cadeia única (imunocitocinas) que podem se ligar a um receptor heterotrimérico incluindo um polipeptídeo receptor-a de interleucina-2 (il-2ra), um polipeptídeo receptor-ß de interleucina-2 (il-2rß) e um polipeptídeo de cadeia gama comum (yc) (e.g., um complexo polipeptídico il-2ra/il-2rß/yc) podem ser administradas a um mamífero para estimular as tregs dentro do mamífero para reduzir ou eliminar uma resposta imunológica neste mamífero. em alguns casos, são fornecidos métodos e materiais que podem ser usados para tratar um mamífero tendo uma condição que pode se beneficiar da redução ou eliminação de uma resposta imunológica dentro do mamífero. por exemplo, uma ou mais imunocitocinas de cadeia única que podem se ligar a um complexo polipeptídico il-2ra/il-2rß/yc podem ser administradas a um mamífero tendo uma condição que pode se beneficiar da redução ou eliminação de uma resposta imunológica para tratar o mamífero.
BR112021026389A 2019-06-26 2020-06-26 Métodos e materiais para expansão direcionada de células t reguladoras BR112021026389A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962867012P 2019-06-26 2019-06-26
PCT/US2020/039854 WO2020264318A1 (en) 2019-06-26 2020-06-26 Methods and materials for targeted expansion of regulatory t cells

Publications (1)

Publication Number Publication Date
BR112021026389A2 true BR112021026389A2 (pt) 2022-04-12

Family

ID=74061346

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021026389A BR112021026389A2 (pt) 2019-06-26 2020-06-26 Métodos e materiais para expansão direcionada de células t reguladoras

Country Status (11)

Country Link
US (1) US20220242946A1 (pt)
EP (1) EP3990004A4 (pt)
JP (1) JP2022539351A (pt)
KR (1) KR20220034133A (pt)
CN (1) CN114286687A (pt)
AU (1) AU2020304654A1 (pt)
BR (1) BR112021026389A2 (pt)
CA (1) CA3145242A1 (pt)
IL (1) IL289376A (pt)
MX (1) MX2022000191A (pt)
WO (1) WO2020264318A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4362969A1 (en) * 2021-06-30 2024-05-08 The Regents of University of California Altering cytokine specificity through binding valency

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0408315A (pt) * 2003-03-14 2006-03-07 Wyeth Corp anticorpo isolado, composição farmacêutica, ácido nucleico isolado, vetor de expressão, célula hospedeira, métodos de produzir um anticorpo, de gerar um anticorpo ou fragmento de ligação de antìgeno, de regular uma resposta imune, de tratar ou prevenir um distúrbio associado com célula imune em um paciente, de tratar ou prevenir um distúrbio hiperproliferativo em um paciente, e, kit de diagnóstico
CN104822704B (zh) * 2012-06-14 2020-02-14 医疗生物科学有限公司 针对分化簇3(cd3)的人源化的抗体
AU2016219350A1 (en) * 2015-02-10 2017-08-24 Minerva Biotechnologies Corporation Humanized anti-MUC1* antibodies
TW201722989A (zh) * 2015-10-23 2017-07-01 輝瑞大藥廠 抗il-2抗體及其組合物及用途
TWI640536B (zh) * 2016-06-20 2018-11-11 克馬伯有限公司 抗體

Also Published As

Publication number Publication date
AU2020304654A1 (en) 2022-02-03
KR20220034133A (ko) 2022-03-17
MX2022000191A (es) 2022-05-06
EP3990004A1 (en) 2022-05-04
IL289376A (en) 2022-02-01
CA3145242A1 (en) 2020-12-30
JP2022539351A (ja) 2022-09-08
US20220242946A1 (en) 2022-08-04
EP3990004A4 (en) 2023-06-07
CN114286687A (zh) 2022-04-05
WO2020264318A1 (en) 2020-12-30

Similar Documents

Publication Publication Date Title
CR20220396A (es) Anticuerpos y proteínas de fusión que se unen a ccr8 y usos de estos
PH12019502621A1 (en) Antibody-cytokine engrafted proteins and methods of use in the treatement of cancer
CY1123783T1 (el) Antiσωμαta enanti-b7-h3 και συζευγματα αντισωματος φαρμακου
BR112023015045A2 (pt) Agonistas de receptores de gpcr, composições farmacêuticas que compreendem os mesmos e métodos para seu uso
BR112021022666A2 (pt) Frações de separação e seus métodos e uso
CY1126062T1 (el) Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1
CL2017001920A1 (es) Anticuerpos humanos contra glicoproteína del virus ébola
BR112018008011A2 (pt) proteínas de ligação triespecíficas e/ou trivalentes para prevenção ou tratamento de infecção por hiv
CO2017002166A2 (es) Proteínas de fusión de interleucina 2 / receptor de interleucina-2 alfa
CL2021002586A1 (es) Anticuerpos de cadena pesada que se unen al psma
WO2020072821A3 (en) Il-12 heterodimeric fc-fusion proteins
MX2022001776A (es) Terapias de combinacion de inmuno oncologia con conjugados de il-2.
BR112018075649A2 (pt) anticorpos anti-b7-h3 e conjugados de fármaco de anticorpo
BR112018072953A2 (pt) polipeptídeos de fusão de cd40l-fc e métodos de uso dos mesmos
MX2021004779A (es) Anticuerpos cd47 novedosos y metodos para usarlos.
BR112023022836A2 (pt) Agonistas de receptores de glp-1 benzimidazoíla, composições farmacêuticas que compreendem os mesmos e métodos para seu uso
BR112019002127A2 (pt) proteína de fusão, vetor, célula, composição farmacêutica, e, uso da proteína de fusão
BR112022006440A2 (pt) Receptor de antígeno quimérico intensificado para manipulação de célula efetora imune e uso do mesmo
BR112021016435A2 (pt) Receptores de antígenos quiméricos responsivos à hipóxia
BR112023020219A2 (pt) Anticorpos anti-il-2r agonistas e métodos de uso
CL2023001433A1 (es) Muteína de il-2; proteína de fusión; ácido nucleico; vector; célula hospedera; métodos; uso
BR112017017609A2 (pt) proteína de fusão fc, e, composição farmacêutica.
CR20220329A (es) Anticuerpos anti–mertk y metodos de uso de los mismos
BR112022005173A2 (pt) Imunocitocina compreendendo complexo de proteína heterodimérica baseado em il-15/il-15ra, ácidos nucleicos, vetor, método célula hospedeira, composições e usos associados
CO2023006790A2 (es) Anticuerpos de cadena pesada que se unen al receptor de folato alfa